Udvalget for Humanmedicinske Lægemidler (CHMP) har konkluderet, at fordelene ved ADROVANCE er større end risiciene ved behandling af osteoporose hos postmenopausale kvinder, som har risiko for D- vitaminmangel.
The Committee for Medicinal products for Human Use (CHMP) decided that ADROVANCE’ s benefits are greater than its risks for the treatment of osteoporosis in postmenopausal women at risk of vitamin D insufficiency.